Amifostine in the treatment of head and neck cancer: Intravenous administration, subcutaneous administration, or none of the above

Journal of Clinical Oncology

Volumn 29, Issue 2, 2011, Pages 119-121

  Eisbruch, Avraham ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; CETUXIMAB; KERATINOCYTE GROWTH FACTOR; PALIFERMIN;

BLOOD PRESSURE MONITORING; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL EFFECTIVENESS; DERMATITIS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG COST; DRUG ERUPTION; DRUG WITHDRAWAL; DYSPHAGIA; EDITORIAL; HEAD AND NECK CANCER; HUMAN; HYPOTENSION; INJECTION SITE PAIN; INTENSITY MODULATED RADIATION THERAPY; MUCOSA INFLAMMATION; NAUSEA; NAUSEA AND VOMITING; PATIENT COMPLIANCE; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION DERMATITIS; XEROSTOMIA;

AMIFOSTINE; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, SUBCUTANEOUS; RADIATION-PROTECTIVE AGENTS;

EID: 79951968327     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.5051     Document Type: Editorial

References (19)

1. Rasey JS, Krohn KA, Menard TW, et al: Comparative biodistribution and radioprotection studies with three radioprotective drugs in mouse tumors. Int J Radiat Oncol Biol Phys 12:1487-1490, 1986 (Pubitemid 16030645)
2. Brizel DM, Wasserman TH, Henke M, et al: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18:3339-3345, 2000
3. Koukourakis MI, Kyrias G, Kakolyris S, et al: Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study. J Clin Oncol 18:2226-2233, 2000 (Pubitemid 30350214)
4. Bardet E, Martin L, Calais G, et al: Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: Final Results of the GORTEC 2000-02 Phase III Randomized Trial. J Clin Oncol 29:127-133, 2011
5. Hensley ML, Hagerty KL, Kewalramani T, et al: American Society of Clinical Oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants. J Clin Oncol 27:127-145, 2009
6. Antonadou D, Pepelassi M, Synodinou M, et al: Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 52:739-747, 2002 (Pubitemid 34158737)
7. Vacha P, Fehlauer F, Mahlmann B, et al: Randomized phase III trial of postoperative amifostine +/- chemoradiotherapy in head and neck cancer. Is there evidence for radioprotection? Strahlenther Onkol 179:385-389, 2003 (Pubitemid 36693262)
8. Buentzel J, Micke O, Adamietz IA, et al: Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: A randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys 64:684-691, 2006 (Pubitemid 43183561)
9. Haddad R, Sonis S, Posner M, et al: Randomized phase 2 study of concomitant chemotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer 115:4514-4523, 2009
10. Hey J, Setz J, Gerlach R, et al: Effect of cisplatin on parotid gland function in concomitant radiochemotherapy. Int J Radiat Oncol Biol Phys 75:1475-1480, 2009
11. Eisbruch A, Kim HM, Terrell JE, et al: Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 50:695-704, 2001 (Pubitemid 32515326)
12. Rudat V, Münter M, Rades D, et al: The effect of amifostine or IMRT to preserve the parotid function after radiotherapy of the head and neck region measured by quantitative salivary gland scintigraphy. Radiother Oncol 89:71-80, 2008
13. Braaksma M, Levendag P: Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation. Semin Oncol 29:63-70, 2002 (6 suppl 19) (Pubitemid 36173251)
14. Brizel DM, Murphy BA, Rosenthal DI, et al: Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol 26:2489-2496, 2008
15. Finch PW, Rubin JS: Keratinocyte growth factor expression and activity in cancer: Implications for use in patients with solid tumors. J Natl Cancer Inst 98:812-824, 2006 (Pubitemid 43923439)
16. Feng FY, Kim HM, Lyden TH, et al: Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: Clinical and functional results. J Clin Oncol 28:2732-2738, 2010
17. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006 (Pubitemid 43209104)
18. Pryor DI, Porceddu SV, Burmeister BH, et al: Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother Oncol 90:172-176, 2009
19. Ang KK, Harris J, Wheeler R, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24-35, 2010